Access cutting-edge sickle cell disease treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access sickle cell disease specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related sickle cell disease treatment provided free
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B). Double-blind period has two parts, 50% (adult only) until the interim analysis (a proof-concept part
Sponsor: Sanofi
Check if you qualify for this sickle cell disease clinical trial in Birmingham, AL
If you're searching for sickle cell disease treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sickle cell disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.